How to take HIV antiretroviral medications on time without a watch in rural Uganda [2]

PLoS Medicine

Volumn 3, Issue 3, 2006, Pages 411-412

  Maier, Marissa ^a   Bwana, Mwebesa ^b   Emenyonu, Nneka ^a   Pepper, Larry ^b   Bangsberg, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE;

ADULT; ANAMNESIS; CASE REPORT; DISEASE COURSE; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LETTER; MALE; POVERTY; RURAL AREA; UGANDA; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; NOTE; PATIENT COMPLIANCE; SOCIAL STATUS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HUMANS; MALE; PATIENT COMPLIANCE; POVERTY; SOCIAL CONDITIONS;

EID: 33645352513     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030161     Document Type: Letter

References (7)

1. Castro A (2005) Adherence to antiretroviral therapy: Merging the clinical and social course of AIDS. PLoS Med 2: e338. DOI: 10.1371/journal.pmed.0020338
2. Russell S (2001 June 8) AIDS activists in uproar over official's remarks on Africa. San Francisco Chronicle; Sect A: 5. Available: http://www.sfgate.com/ cgi-bin/article.cgi?f=/c/a/2001/06/08/MN164875.DTL. Accessed 7 February 2006.
3. Stevens W, Kaye S, Corrah T (2004) Antiretroviral therapy in Africa. BMJ 328: 280-282.
4. Joint United Nations Programme on HIV/AIDS [UNAIDS] (2004) Report on the global AIDS epidemic: Executive summary. Geneva: UNAIDS. Available: http://www.unaids.org/bangkok2004/GAR2004_html/ExecSummary_en/ExecSumm_00_en. htm. Accessed 7 February 2006.
5. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36: 1100-1102.
6. Orrell C, Bangsberg D, Badri M, Wood R (2003) Adherence is not a barrier to delivery of HIV antiretroviral therapy in resource-poor countries. AIDS 17: 1369-1375.
7. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, et al. (2004) Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: Open-label multicentre trial. Lancet 364: 29-34.